Sana Biotechnology Inc. (SANA) is poised for a pivotal year in 2024, with plans to release preliminary data from its four ongoing clinical trials spanning seven different indications.
The company is focused on creating engineered cells as medicines for patients based on its hypoimmune technology. Its pipeline of drug candidates is strategically divided into three key categories - Oncology, B-cell Mediated Autoimmune Disease, and Regenerative Medicine.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com